{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:46:11Z","timestamp":1770140771906,"version":"3.49.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00508-024-02370-0","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:01:58Z","timestamp":1715677318000},"page":"75-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["H\u00e4mophilie-Behandlung in \u00d6sterreich","Treatment of haemophilia in Austria"],"prefix":"10.1007","volume":"136","author":[{"given":"Christoph","family":"Male","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Crevenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Eichinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Feistritzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"F\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Haushofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kurringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Neumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Puchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Rettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Streif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Thom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Wissmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Zwiauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"2370_CR1","doi-asserted-by":"publisher","unstructured":"Pabinger I, Heistinger M, Muntean W, Reitter-Pfoertner SE, Rosenlechner S, Schindl T, Schuster G, Streif W, Thom K, Male C. H\u00e4mophiliebehandlung in \u00d6sterreich. Wien Klin Wochenschr 2015;127[Suppl 3]:115\u2013130. https:\/\/doi.org\/10.1007\/s00508-015-0872-x.","DOI":"10.1007\/s00508-015-0872-x"},{"key":"2370_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava\u00a0A, Santagostino\u00a0E, Dougall\u00a0A, et\u00a0al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:1\u2013158.","journal-title":"Haemophilia"},{"key":"2370_CR3","unstructured":"WFH. Report on the Annual Global Survey. 2022. https:\/\/elearning.wfh.org\/resource\/report-on-the-annual-global-survey-2022\/."},{"key":"2370_CR4","unstructured":"Schulman S. Mild Hemophilia\u2014Revised. Edition. 2012;(41). 2012 [2014\/09\/09]; Available from: http:\/\/www.wfh.org\/en\/page.aspx?pid=1270."},{"key":"2370_CR5","unstructured":"University College London. Factor VIII Variant Database. [2024-01-31]; Available from: http:\/\/www.factorviii-db.org\/."},{"issue":"2","key":"2370_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-2516.2007.01625.x","volume":"14","author":"BT Colvin","year":"2008","unstructured":"Colvin\u00a0BT, Astermark\u00a0J, Fischer\u00a0K, et\u00a0al. European principles of haemophilia care. Haemophilia. 2008;14(2):361\u201374.","journal-title":"Haemophilia"},{"key":"2370_CR7","doi-asserted-by":"crossref","unstructured":"Endler G, Slavka G, Perkmann T, Haushofer A. [The importance of preanalytics for the coagulation laboratory]. H\u00e4mostaseologie. 2010;30(2):63\u201370. Epub 2010\/05\/11. Die Bedeutung der Praanalytik fur das Gerinnungslabor.","DOI":"10.1055\/s-0037-1617045"},{"key":"2370_CR8","isbn-type":"print","volume-title":"Ligatur-Verlag","author":"P Kn\u00f6bl","year":"2009","unstructured":"Kn\u00f6bl\u00a0P, Erworbene Hemmk\u00f6rper-H\u00e4mophilie\u00a0SM. Ligatur-Verlag. 2009. ISBN 978-3-940407-19\u20111.","ISBN":"https:\/\/id.crossref.org\/isbn\/9783940407191"},{"key":"2370_CR9","unstructured":"Wissenschaftlicher Beirat der \u00d6sterreichischen H\u00e4mophilie Gesellschaft. Konsensus \u00fcber die Verwendung von Faktorenkonzentraten bei Patienten mit H\u00e4mophilie (Version v. Nov. 2020). Available from: https:\/\/bluter.at\/wp\/wp-content\/uploads\/2021\/02\/Konsensus-des-Wissenschaftlichen-Beirates-zur-Therapie-der-Haemophilie.pdf"},{"issue":"9","key":"2370_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/2040620718796429","volume":"9","author":"T Lambert","year":"2018","unstructured":"Lambert\u00a0T, Benson\u00a0G, Dolan\u00a0G, et\u00a0al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295\u2013308.","journal-title":"Ther Adv Hematol"},{"key":"2370_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","volume":"397","author":"ME Mancuso","year":"2021","unstructured":"Mancuso\u00a0ME, Mahlangu\u00a0JN, Pipe\u00a0SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397:630\u201340.","journal-title":"Lancet"},{"key":"2370_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13013","volume":"22","author":"P Collins","year":"2016","unstructured":"Collins\u00a0P, Chalmers\u00a0E, Chowdary\u00a0P, et\u00a0al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487\u201398.","journal-title":"Haemophilia"},{"issue":"1","key":"2370_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava\u00a0A, Brewer\u00a0AK, Mauser-Bunschoten\u00a0EP, et\u00a0al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1\u201347.","journal-title":"Haemophilia"},{"key":"2370_CR14","doi-asserted-by":"publisher","unstructured":"Callaghan MU, Negrier C, Paz-Priel I, et\u00a0al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20114\u00a0studies. Blood 2021 Apr 22;137(16):2231\u20132242. https:\/\/doi.org\/10.1182\/blood.2020009217","DOI":"10.1182\/blood.2020009217"},{"key":"2370_CR15","doi-asserted-by":"crossref","unstructured":"Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jim\u00e9nez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143:1355\u20131364.","DOI":"10.1182\/blood.2023021832"},{"key":"2370_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jha2.442","volume":"3","author":"D Swan","year":"2022","unstructured":"Swan\u00a0D, Mahlangu\u00a0J, Thachil\u00a0J. Non-factor therapies for bleeding disorders: A\u00a0primer for the general haematologist. EJHaem. 2022;3:584\u201395.","journal-title":"EJHaem."},{"issue":"11","key":"2370_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo\u00a0MC, Mahlangu\u00a0J, Pasi\u00a0KJ, et\u00a0al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N\u00a0Engl J Med. 2022;386(11):1013\u201325.","journal-title":"N Engl J Med"},{"issue":"8","key":"2370_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu\u00a0J, Kaczmarek\u00a0R, von Drygalski\u00a0A, et\u00a0al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N\u00a0Engl J Med. 2023;388(8):694\u2013705.","journal-title":"N Engl J Med"},{"issue":"8","key":"2370_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe\u00a0SW, Leebeek\u00a0FWG, Recht\u00a0M, et\u00a0al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N\u00a0Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"key":"2370_CR20","doi-asserted-by":"crossref","unstructured":"Coppens M, Pipe SW, Miesbach W, et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.; HOPE-B Investigators. Lancet Haematol. 2024 Apr;11(4):e265-e275.","DOI":"10.1016\/S2352-3026(24)00006-1"},{"key":"2370_CR21","doi-asserted-by":"publisher","unstructured":"Miesbach W, Chowdary P, Coppens M, et\u00a0al. Delivery of AAV-based gene therapy through haemophilia centres\u2014A need for re-evaluation of infrastructure and comprehensive care: A\u00a0Joint publication of EAHAD and EHC. Haemophilia. 2021 Nov;27(6):967\u2013973. https:\/\/doi.org\/10.1111\/hae.14420. Epub 2021 Sep 22.","DOI":"10.1111\/hae.14420"},{"issue":"3","key":"2370_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1055\/a-1957-4477","volume":"43","author":"W Miesbach","year":"2023","unstructured":"Miesbach\u00a0W, Oldenburg\u00a0J, Klamroth\u00a0R, et\u00a0al. Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH). Haemostaseologie. 2023;43(3):196\u2013207. https:\/\/doi.org\/10.1055\/a-1957-4477.","journal-title":"Haemostaseologie"},{"key":"2370_CR23","unstructured":"AWMF-Leitlinie \u201eTherapie angeborener thrombozyt\u00e4rer Erkrankungen\u201c, AWMF-Register Nr. 086-004, Klasse: S2K, erh\u00e4ltlich unter http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/086-004.html. Accessed 2024-01-31."},{"key":"2370_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1365-2516.2008.01695.x","volume":"14(4","author":"D Keeling","year":"2008","unstructured":"Keeling\u00a0D, Tait\u00a0C, Makris\u00a0M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A\u00a0United Kingdom Haemophilia Center Doctors\u2019 Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4:671\u201384.","journal-title":"Haemophilia"},{"issue":"4","key":"2370_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJM199807233390407","volume":"339","author":"PM Mannucci","year":"1998","unstructured":"Mannucci\u00a0PM. Hemostatic drugs. N\u00a0Engl J Med. 1998;339(4):245\u201353.","journal-title":"N Engl J Med"},{"key":"2370_CR26","doi-asserted-by":"publisher","unstructured":"van Galen KP, Engelen ET, Mauser-Bunschoten EP, et\u00a0al. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2019 Apr 19;4(4):CD011385. https:\/\/doi.org\/10.1002\/14651858.CD011385.pub3","DOI":"10.1002\/14651858.CD011385.pub3"},{"key":"2370_CR27","doi-asserted-by":"publisher","unstructured":"Ullah K, Mukhtar H, Khalid U, et\u00a0al. Is Antifibrinolytic Therapy Effective for Preventing Hemorrhage in Patients with Hemophilia Undergoing Dental Extractions? A\u00a0Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221114862. https:\/\/doi.org\/10.1177\/10760296221114862.","DOI":"10.1177\/10760296221114862"},{"key":"2370_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1365-2516.2008.01952.x","volume":"15(2","author":"PL Giangrande","year":"2009","unstructured":"Giangrande\u00a0PL, Wilde\u00a0JT, Madan\u00a0B, et\u00a0al. Consensus protocol for the use of recombinant activated factor\u00a0VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009;15(2:501\u20138.","journal-title":"Haemophilia"},{"issue":"4","key":"2370_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","volume":"149","author":"M Richards","year":"2010","unstructured":"Richards\u00a0M, Williams\u00a0M, Chalmers\u00a0E, et\u00a0al. A\u00a0United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor\u00a0VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149(4):498\u2013507.","journal-title":"Br J Haematol"},{"key":"2370_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1160\/TH15-08-0664","volume":"115","author":"R Ljung","year":"2016","unstructured":"Ljung\u00a0R, Fischer\u00a0K, Carcao\u00a0M, al group\u00a0INPH. Practical considerations in choosing a\u00a0factor\u00a0VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thromb Haemost. 2016;115:913\u201320.","journal-title":"Thromb Haemost"},{"issue":"6","key":"2370_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1046\/j.1365-2516.2002.00695.x","volume":"8","author":"K Fischer","year":"2002","unstructured":"Fischer\u00a0K, van der Bom\u00a0JG, Molho\u00a0P, et\u00a0al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a\u00a0comparison of costs and long-term outcome. Haemophilia. 2002;8(6):745\u201352.","journal-title":"Haemophilia"},{"key":"2370_CR32","unstructured":"S2k-Leitlinie Synovitis bei H\u00e4mophilie. Version\u00a02.0. Stand 15. Jan. 2022. AWMF-Registernummer: 086-005. Abrufbar unter: http:\/\/www.awmf.org\/leitlinien\/detail\/ll\/086-005.html. Accessed 2024-01-31."},{"key":"2370_CR33","doi-asserted-by":"crossref","unstructured":"Stromer W, Pabinger I, Ay C, et\u00a0al. Pain management in hemophilia: expert recommendations. WKWO 2021;133(19\u201320):1042\u20131056.","DOI":"10.1007\/s00508-020-01798-4"},{"key":"2370_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00482-018-0321-7","volume":"32","author":"W Stromer","year":"2018","unstructured":"Stromer\u00a0W, Messerer\u00a0B, Crevenna\u00a0R, et\u00a0al. Schmerztherapie bei Kindern und Jugendlichen mit H\u00e4mophilie. Handlungsempfehlungen einer Expertengruppe. Schmerz. 2018;32:404\u201318.","journal-title":"Schmerz"},{"issue":"2","key":"2370_CR35","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1542\/peds.101.2.e1","volume":"101","author":"A Taddio","year":"1998","unstructured":"Taddio\u00a0A, Ohlsson\u00a0A, Einarson\u00a0TR, et\u00a0al. A\u00a0systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. Pediatrics. 1998;101(2):E1. https:\/\/doi.org\/10.1542\/peds.101.2.e1.","journal-title":"Pediatrics"},{"key":"2370_CR36","unstructured":"World Federation of Hemophilia (WFH). Compendium of assessment tools. [2013\/10\/01]; Available from: http:\/\/www.wfh.org\/en\/page.aspx?pid=882."},{"issue":"[Suppl3","key":"2370_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2516.2008.01709.x","volume":"14","author":"A Gringeri","year":"2008","unstructured":"Gringeri\u00a0A, Von Mackensen\u00a0S. Quality of life in haemophilia. Haemophilia. 2008;14([Suppl3):19\u201325.","journal-title":"Haemophilia"},{"issue":"2","key":"2370_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/rth2.12195","volume":"3","author":"BA Konkle","year":"2019","unstructured":"Konkle\u00a0BA, Skinner\u00a0M, Iorio\u00a0A. Hemophilia trials in the twenty-first century: Defining patient important outcomes. Res Pract Thromb Haemost. 2019;3(2):184\u201392.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2370_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/hae.13120","volume":"22","author":"K Fischer","year":"2016","unstructured":"Fischer\u00a0K, de Kleij\u00a0P, Negrier\u00a0C, et\u00a0al. The association of haemophilic arthropathy with Health-Related Quality of Life: a\u00a0post hoc analysis. Haemophilia. 2016;22(6):833\u201340.","journal-title":"Haemophilia"},{"key":"2370_CR40","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/hae.12959","volume":"22","author":"A Njidam","year":"2016","unstructured":"Njidam\u00a0A, Foppen\u00a0W, van der Schouw\u00a0YT, et\u00a0al. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia. 2016;22:852\u20138.","journal-title":"Haemophilia"},{"issue":"6","key":"2370_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson\u00a0MJ, Abshire\u00a0TC, Shapiro\u00a0AD, et\u00a0al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N\u00a0Engl J Med. 2007;357(6):535\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"2370_CR42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2516.2009.02122.x","volume":"16","author":"K Kurnik","year":"2010","unstructured":"Kurnik\u00a0K, Bidlingmaier\u00a0C, Engl\u00a0W, et\u00a0al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16(2):256\u201362. Mar.","journal-title":"Haemophilia"},{"issue":"5","key":"2370_CR43","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/hae.12666","volume":"21","author":"G Auerswald","year":"2015","unstructured":"Auerswald\u00a0G, Kurnik\u00a0K, Aledort\u00a0LM, et\u00a0al. EPIC clinical study group. The EPIC study: a\u00a0lesson to learn. Haemophilia. 2015;21(5):622\u20138. Sep.","journal-title":"Haemophilia"},{"issue":"11","key":"2370_CR44","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","volume":"1;109","author":"SC Gouw","year":"2007","unstructured":"Gouw\u00a0SC, van der Bom\u00a0JG, van den Berg\u00a0MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A:\u00a0the CANAL cohort study. Blood. 2007;1;109(11):4648\u201354. Jun.","journal-title":"Blood"},{"key":"2370_CR45","doi-asserted-by":"publisher","unstructured":"Pipe SW, Collins PW, Dhalluin C, et\u00a0al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a\u00a0phase\u00a03b, open-label trial. Blood. 2023 Dec 21:blood.2023021832. https:\/\/doi.org\/10.1182\/blood.2023021832.","DOI":"10.1182\/blood.2023021832"},{"key":"2370_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14412","author":"ME Mancuso","year":"2021","unstructured":"Mancuso\u00a0ME, Male\u00a0C, Kenet\u00a0G, et\u00a0al. Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia. 2021; https:\/\/doi.org\/10.1111\/hae.14412.","journal-title":"Haemophilia"},{"issue":"1","key":"2370_CR47","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1111\/hae.12569","volume":"21","author":"SL Carpenter","year":"2015","unstructured":"Carpenter\u00a0SL, Soucie\u00a0JM, Presley\u00a0RJ, et\u00a0al. Hepatitis\u00a0B vaccination is effective by subcutaneous route in children with bleeding disorders: a\u00a0universal data collection database analysis. Haemophilia. 2015;21(1):e39\u201343.","journal-title":"Haemophilia"},{"key":"2370_CR48","doi-asserted-by":"crossref","unstructured":"Kroger AT, Atkinson WL, Pickering LK. 8\u2014General immunization practices. In: Offit PA, Plotkin SA, Orenstein WA, editors. Vaccines (Sixth Edition). London: W.B. Saunders; 2013. p.\u00a088\u2013112.","DOI":"10.1016\/B978-1-4557-0090-5.00002-1"},{"key":"2370_CR49","unstructured":"Injektionsweg mit Fokus Injektion bei Blutungsneigung. https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/Stichwortliste\/G\/Injektionsort_Tabelle.pdf. Accessed 2024-01-31."},{"issue":"5","key":"2370_CR50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/hae.14586","volume":"28","author":"A Tiede","year":"2022","unstructured":"Tiede\u00a0A, Leise\u00a0H, Horneff\u00a0S, et\u00a0al. Safety of intramuscular COVID-19 vaccination in patients with haemophilia. Haemophilia. 2022;28(5):687\u201393. Sep.","journal-title":"Haemophilia"},{"issue":"3","key":"2370_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1055\/a-1401-2691","volume":"41","author":"C Pfrepper","year":"2021","unstructured":"Pfrepper\u00a0C, Holstein\u00a0K, K\u00f6nigs\u00a0C, et\u00a0al. Hemophilia Board of the German, Austrian, Swiss Society on Thrombosis Hemostasis Research (GTH). Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. Hamostaseologie. 2021;41(3):190\u20136. Jun.","journal-title":"Hamostaseologie"},{"key":"2370_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1046\/j.1365-2516.2003.00840.x","volume":"10","author":"LA Valentino","year":"2004","unstructured":"Valentino\u00a0LA, Ewenstein\u00a0B, Navickis\u00a0RJ, Wilkes\u00a0MM. Central venous access devices in haemophilia. Haemophilia. 2004;10:134\u201346.","journal-title":"Haemophilia"},{"key":"2370_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/hae.13433","volume":"24","author":"KE Thom","year":"2018","unstructured":"Thom\u00a0KE, Hoelzenbein\u00a0T, Jones\u00a0N, et\u00a0al. Arterio-venous shunts as venous access in children with haemophilia. Haemophilia. 2018;24:429\u201335.","journal-title":"Haemophilia"},{"issue":"6","key":"2370_CR54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/hae.12488","volume":"20","author":"VR Breakey","year":"2014","unstructured":"Breakey\u00a0VR, Ignas\u00a0DM, Warias\u00a0AV, et\u00a0al. A\u00a0pilot randomized control trial to evaluate the feasibility of an Internet-based self-management and transitional care program for youth with haemophilia. Haemophilia. 2014;20(6):784\u201393.","journal-title":"Haemophilia"},{"issue":"6","key":"2370_CR55","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hae.13621","volume":"24","author":"LG Mortensen","year":"2018","unstructured":"Mortensen\u00a0LG, Strand\u00a0AM, Almen\u00a0L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a\u00a0qualitative review. Haemophilia. 2018;24(6):862\u201372.","journal-title":"Haemophilia"},{"issue":"5","key":"2370_CR56","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1365-2516.2009.02036.x","volume":"15","author":"CE Walsh","year":"2009","unstructured":"Walsh\u00a0CE, Valentino\u00a0LA. Factor VIII prophylaxis for adult patients with severe haemophilia A:\u00a0results of a\u00a0US survey of attitudes and practices. Haemophilia. 2009;15(5):1014\u201321.","journal-title":"Haemophilia"},{"key":"2370_CR57","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ, Lundin B, Funk S, et\u00a0al. Effect of late prophylaxis in hemophilia on joint status: a\u00a0randomized trial. Journal Thromb Haemost 2017;15(11):2115\u20132124.","DOI":"10.1111\/jth.13811"},{"issue":"5","key":"2370_CR58","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1160\/TH15-08-0637","volume":"115","author":"A Nijdam","year":"2016","unstructured":"Nijdam\u00a0A, Foppen\u00a0W, De Kleijn\u00a0P, et\u00a0al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost. 2016;115(5):931\u20138.","journal-title":"Thromb Haemost"},{"key":"2370_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2016.10.015","volume":"148","author":"K Holstein","year":"2016","unstructured":"Holstein\u00a0K, Batorova\u00a0A, Carvalho\u00a0M, et\u00a0al. Current view and outcome of ITI therapy\u2014A change over time? Thromb Res. 2016;148:38\u201344.","journal-title":"Thromb Res"},{"key":"2370_CR60","doi-asserted-by":"publisher","first-page":"204062072110070","DOI":"10.1177\/20406207211007058","volume":"12","author":"K Khair","year":"2021","unstructured":"Khair\u00a0K, Chalmers\u00a0E, Flannery\u00a0T, et\u00a0al. Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a\u00a0modified Delphi consensus study. Ther Adv Hematol. 2021;12:20406207211007058.","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2370_CR61","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1034\/j.1600-0609.2003.00077.x","volume":"70","author":"K Ghosh","year":"2003","unstructured":"Ghosh\u00a0K, Jijina\u00a0F, Mohanty\u00a0D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410\u20132.","journal-title":"Eur J Haematol"},{"issue":"2","key":"2370_CR62","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jemermed.2007.12.024","volume":"39","author":"T Singleton","year":"2010","unstructured":"Singleton\u00a0T, Kruse-Jarres\u00a0R, Leissinger\u00a0C. Emergency department care for patients with hemophilia and von Willebrand disease. J\u00a0Emerg Med. 2010;39(2):158\u201365.","journal-title":"J Emerg Med"},{"issue":"11","key":"2370_CR63","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette\u00a0VS, Key\u00a0NS, Ljung\u00a0LR, et\u00a0al. Definitions in hemophilia: communication from the SSC of the ISTH. J\u00a0Thromb Haemost. 2014;12(11):1935\u20139. Nov.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2370_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/hae.13928","volume":"26","author":"B Bajkin","year":"2020","unstructured":"Bajkin\u00a0B, Dougall\u00a0A. Current state of play regarding dental extractions in patients with haemophilia: Consensus or evidence-based practice? A\u00a0review of the literature. Haemophilia. 2020;26(2):183\u201399. Mar.","journal-title":"Haemophilia"},{"issue":"S4","key":"2370_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/hae.14551","volume":"28","author":"ME Mancuso","year":"2022","unstructured":"Mancuso\u00a0ME, Apte\u00a0S, Hermans\u00a0C. Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022. Haemophilia. 2022;28(S4):93\u2013102.","journal-title":"Haemophilia"},{"key":"2370_CR66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood.2019000658","volume":"134","author":"HM van den Berg","year":"2019","unstructured":"van den Berg\u00a0HM, Fischer\u00a0K, Carcao\u00a0M, et\u00a0al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134:317\u201320.","journal-title":"Blood"},{"key":"2370_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3324\/haematol.2019.239160","volume":"106","author":"C Male","year":"2021","unstructured":"Male\u00a0C, Gretenkort\u00a0N, Rafowicz\u00a0A, et\u00a0al. on behalf of the PedNet study group. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a\u00a0PedNet study. Haematologica. 2021;106:123\u20139.","journal-title":"Haematologica"},{"key":"2370_CR68","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jth.13711","volume":"15","author":"AS van Velzen","year":"2017","unstructured":"van Velzen\u00a0AS, Eckhardt\u00a0CL, Peters\u00a0M, et\u00a0al. Intensity of factor\u00a0VIII treatment and the development of inhibitors in non-severe in non-severe hemophilia A patients: results of the INSIGHT case-control study. J\u00a0Thromb Haemost. 2017;15:1422\u20139.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2370_CR69","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/s-0029-1245107","volume":"35","author":"B Verbruggen","year":"2009","unstructured":"Verbruggen\u00a0B, van Heerde\u00a0WL, Laros-van Gorkom\u00a0BA. Improvements in factor\u00a0VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost. 2009;35(8):752\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2370_CR70","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","volume":"109","author":"J Astermark","year":"2007","unstructured":"Astermark\u00a0J, Donfield\u00a0SM, DiMichele\u00a0DM, et\u00a0al. A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546\u201351.","journal-title":"Blood"},{"key":"2370_CR71","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/hae.12028","volume":"19(2","author":"S Rangarajan","year":"2013","unstructured":"Rangarajan\u00a0S, Austin\u00a0S, Goddard\u00a0NJ, et\u00a0al. Consensus recommendations for the use of FEIBA\u00ae) in haemophilia A patients with inhibitors undergoing elective orthopaedic and nonorthopaedic surgery. Haemophilia. 2013;19(2:294\u2013303.","journal-title":"Haemophilia"},{"key":"2370_CR72","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2516.2010.02460.x","volume":"17(4","author":"LA Valentino","year":"2011","unstructured":"Valentino\u00a0LA, Cooper\u00a0DL, Goldstein\u00a0B. Surgical experience with rFVIIa (NovoSeven\u00ae) in congenital haemophilia A and\u00a0B patients with inhibitors to factors VIII or IX. Haemophilia. 2011;17(4:579\u201389.","journal-title":"Haemophilia"},{"key":"2370_CR73","unstructured":"Fachinformation NovoSeven. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novoseven-epar-product-information_en.pdf."},{"key":"2370_CR74","unstructured":"Fachinformation FEIBA. https:\/\/www.takeda-produkte.de\/system\/files\/produkt-info\/fachinformation-feiba-nf-500-e1000-e-pulver-und-losungsmittel-zur-herstellung-einer-injektionslosung.pdf."},{"key":"2370_CR75","unstructured":"Fachinformation Cevenfacta. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cevenfacta-epar-product-information_en.pdf."},{"issue":"5","key":"2370_CR76","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/hae.13264","volume":"23","author":"P Collins","year":"2017","unstructured":"Collins\u00a0P, Chalmers\u00a0E, Alamelu\u00a0J, et\u00a0al. First-line immune tolerance induction for children with severe haemophilia A: A\u00a0protocol from the UK Haemophilia Centre Doctors\u2019 Organisation Inhibitor and Paediatric Working Parties. Haemophilia. 2017;23(5):654\u20139. Sep.","journal-title":"Haemophilia"},{"key":"2370_CR77","doi-asserted-by":"crossref","unstructured":"Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335\u201344.","DOI":"10.1182\/blood-2011-08-369132"},{"issue":"5","key":"2370_CR78","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/hae.13819","volume":"25","author":"G Batsuli","year":"2019","unstructured":"Batsuli\u00a0G, Zimowski\u00a0KL, Tickle\u00a0K, et\u00a0al. Epub 2019 Aug 2. Haemophilia. 2019;25(5):789\u201396.","journal-title":"Haemophilia"},{"key":"2370_CR79","doi-asserted-by":"crossref","unstructured":"Holstein\u00a0K, Albisetti\u00a0M, Bidlingmaier\u00a0C, et\u00a0al. on behalf of the \u2018St\u00e4ndige Kommission H\u00e4mophilie\u2019 (Haemophilia board) of the German, Austrian, Swiss Society for Thrombosis Haemostasis Research (GTH). Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A. Haemostaseologie 2020;40:561-571.","DOI":"10.1055\/a-1127-6476"},{"key":"2370_CR80","first-page":"226","volume":"40","author":"W Streif","year":"2020","unstructured":"Streif\u00a0W, Kn\u00f6fler\u00a0R. Perinatal Management of Haemophilia. Haemostaseologie. 2020;40:226\u201332.","journal-title":"Haemophilia. Haemostaseologie."},{"key":"2370_CR81","unstructured":"https:\/\/www.gesundheit.gv.at\/leben\/eltern\/schwangerschaft\/info\/schwangerschaftsabbruch. (accessed 2024-01-31)"}],"updated-by":[{"DOI":"10.1007\/s00508-024-02421-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000}},{"DOI":"10.1007\/s00508-024-02384-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000}}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02370-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:16:02Z","timestamp":1724915762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02370-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":81,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2370"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02370-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00508-024-02421-6","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s00508-024-02384-8","asserted-by":"object"}]},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"17 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00508-024-02421-6","URL":"https:\/\/doi.org\/10.1007\/s00508-024-02421-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00508-024-02384-8","URL":"https:\/\/doi.org\/10.1007\/s00508-024-02384-8","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Male: Pr\u00fcfer bei klinischen Pr\u00fcfungen mit Faktorkonzentraten von Bayer, Biotest, Novo Nordisk, Swedish Orphan Biovitrum, Takeda. Unrestricted Research Grant an die Medizinische Universit\u00e4t Wien von CSL Behring, Swedish Orphan Biovitrum. Honorare (Beratung, Vortr\u00e4ge, Vorsitze) von Bayer, Biomarin, Biotest, Bioproducts Laboratory, CSL Behring, LFB, Novo Nordisk, Pfizer, Roche, Swedish Orphan Biovitrum, Takeda. C.\u00a0Ay: Pr\u00fcfer bei klinischen Pr\u00fcfungen mit Pr\u00e4paraten von Novo Nordisk und Sobi. Vortragst\u00e4tigkeit und\/oder Teilnahme an Advisory Boards der Firmen Bayer, Biotest, CSL Behring, LFB, Novo Nordisk, Roche, Pfizer, Takeda, Sobi. S.\u00a0Eichinger: Vortragshonorare, Vorsitzende bei Symposien der Firmen CSL Behring, Takeda, Novo Nordisk, Pfizer. C.\u00a0Feistritzer: Forschungsf\u00f6rderung, Beratert\u00e4tigkeit, Vortragshonorare und Unterst\u00fctzung bei Kongressteilnahmen f\u00fcr: Bayer, CSL Behring, Biomarin, Biotest, Novo Nordisk, Roche, Sobi, Takeda. A.\u00a0Haushofer: Vortragshonorare von: Baxter, Shire, Takeda, Roche Austria, Novo Nordisk, Sobi; Forschungsgrants: Shire (\u00d6GLMKC), Novo Nordisk (\u00d6GLMKC); Reiseunterst\u00fctzungen: Baxter, Shire, Takeda. P.\u00a0Neumeister: Honorare von Amgen, Celgene BMS, Janssen, GSK, Sanofi, Takeda, Roche. J.\u00a0Rettl: Honorare f\u00fcr einzelne Vortr\u00e4ge und Advisory Boards: Amgen, Astra Zeneca, Bayer, BeiGene, BioMarin, BMS, CSL Behring, Janssen, LFB, Novartis, Novo Nordisk, Pfizer, Roche, SOBI, Takeda. G.\u00a0Schuster: Teilnahme an Advisory Boards der Firmen CSL Behring, Novo Nordisk, Pfizer und SOBI. R.\u00a0Schwarz: Honorare f\u00fcr Advisory-Board-Meetings: Novo Nordisk, CSL Behring, Sobi, Pfizer, Roche, Takeda\/Baxalta. M.\u00a0Sohm: Honorare f\u00fcr einzelne Vortr\u00e4ge oder Advisory-Board-Meetings der Firmen Bayer, CSL Behring, Novo Nordisk, SOBI und Roche. W.\u00a0Streif: Vortrags\u2011\/Schulungshonorare, Gutachtert\u00e4tigkeit und Forschungsunterst\u00fctzung\/Durchf\u00fchrung klinischer Studien von Biotest, Bayer, CSL Behring, Novo Nordisk, \u00d6HG, Roche, SOBI, Octapharma, Takeda. Zertifizierungshonorare von ClarCert. Autorenhonorare von Thieme. Mitglied des Editorial Boards der Zeitschrift. \u201eH\u00e4mostaseologie\u00a0\u2013 Progress in Haemomstasis\u201c. Mitglied des Vorstands der \u00d6GKJ, des wissenschaftlichen Beirats der \u00d6HG, Mitglied der GTH. K.\u00a0Thom: Pr\u00fcferin bei klinischen Pr\u00fcfungen mit Faktorkonzentraten von Baxter, Bayer, CSL Behring, Novo Nordisk, Pfizer, Octapharma. Honorare f\u00fcr einzelne Vortr\u00e4ge oder Advisory-Board-Meetings der Firmen Novo Nordisk, SOBI, Bayer, CSL Behring und Roche. E.\u00a0Wissmann: Honorarnoten f\u00fcr Vortr\u00e4ge, Mitautorenschaft, Online-Videos, Schulungen von CSL Behring, Takeda, Pfizer, Roche, Chiesi, Bayer. I.\u00a0Pabinger: Pr\u00fcferin bei klinischen Pr\u00fcfungen mit Faktorkonzentraten von Baxter, Bayer, CSL Behring, Novo Nordisk, Pfizer, Octapharma, Sobi. Honorare f\u00fcr einzelne Vortr\u00e4ge oder Advisory-Board-Meetings der Firmen Bayer, Biotest, CSL Behring, Novo-NordiskPfizer, Roche, Sobi und Takeda. Unrestricted Research Grants an die Medizinische Universit\u00e4t Wien der Firma CSL Behring, Sobi, Roche-Diagnostics. R.\u00a0Crevenna, R.\u00a0F\u00fcller, A.\u00a0Kurringer, S.\u00a0Puchner, T.\u00a0Schindl, B.\u00a0Wagner und K.\u00a0Zwiauer geben an, dass kein Interessenkonflikt besteht. Organisation und Durchf\u00fchrung der Leitlinien-Meetings und des nachfolgenden Abstimmungsprozesses sowie die Publikation dieser Leitlinie wurden durch die \u00d6sterreichische H\u00e4mophilie Gesellschaft (\u00d6HG) finanziert. Keine(r) der Autor:innen hat f\u00fcr die Erstellung der Leitlinien ein Honorar erhalten.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}